Search Results - "Stringer, Megan"

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.

Authors: Goodlett, Charles R. Stringer, Megan LaCombe, Jonathan et al.

Source: Scientific Reports. 6/26/2020, Vol. 10 Issue 1, p1-17. 17p.

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.

Authors: Stringer, Megan Goodlett, Charles R. Roper, Randall J.

Source: Molecular Genetics & Genomic Medicine. Sep2017, Vol. 5 Issue 5, p451-465. 15p.

This result is not displayed to guests.
Login for full access.

Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.

Authors: Stringer, Megan Abeysekera, Irushi Dria, Karl J. et al.

Source: Pharmacology, Biochemistry & Behavior. Nov2015, Vol. 138, p70-79. 10p.

Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model.

Authors: Hawley, Laura E. Stringer, Megan Deal, Abigail J. et al.

Source: Neurobiology of Disease. Jan2024, Vol. 190, pN.PAG-N.PAG. 1p.

This result is not displayed to guests.
Login for full access.

Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.

Authors: Hawley, Laura E. Prochaska, Faith Stringer, Megan et al.

Source: Pharmacology, Biochemistry & Behavior. Jun2022, Vol. 217, pN.PAG-N.PAG. 1p.